CTIBiotech - Transgene Collaboration for Cancer Research
Lyon, France--(Newsfile Corp. - November 6, 2019) - CTIBioTumour, a CTIBiotech technology, aims to reduce by half the time required for the preclinical evaluation of anti-cancer treatments and to save up to 20% on drug development costs. Histology staining of 3D-printed human tumour. To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/6648/4
2019-11-06 11:39 AM EST